BRAF inhibition with Dabrafenib and MEK inhibition with Trametinib, either as monotherapy or in combination, lead to the suppression of phosphorylated ERK (pERK) in melanoma cells [20]. This evidence concerns the gene MAP2K7 and melanoma.